The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid progenitor and precursor cells at different stages of differentiation, which play an important role in tumor immunosuppression. Glioma is the most common and deadliest primary malignant tumor of the brain, and ample evidence supports key contributions of MDSCs to the immunosuppressive tumor microenvironment, which is a key factor stimulating glioma progression. In this review, we summarize the source and characterization of MDSCs, discuss their immunosuppressive functions, and current approaches that target MDSCs for tumor control. Overall, the review provides insights into the roles of MDSC immunosuppression in the glioma microenvironment and suggests that MDSC control is a powerful cellular therapeutic target for currently incurable glioma tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“The downregulation of IL12 is further exacerbated by the macrophages themselves, because the production of IL-10 of macrophages is also promoted by MDSCs (76).”
BackgroundTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775 · cited 1×
“apoptosis from the microenvironment by enhancing the activity of ARG1, inducible iNOS and increase the uptake mediated by the CAT-2B transporter (62, 63).”
BackgroundHuang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Gerard, C., & Rollins, B. J. (2001) · Nature Immunology · doi:10.1038/84209 · Cited by 1,357
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140 · cited 2×
“MDSCs can produce angiogenic factors such as VEGF and basic fibroblast growth factor (bFGF) to promote tumor angiogenesis (90, 91).”
BackgroundDisruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Highfill, S. L., Cui, Y., Giles, A. J., Smith, J. P., Zhang, H., Morse, E., Kaplan, R. N., & Mackall, C. L. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007974 · Cited by 767 · cited 1×
“The chemokine receptor CXCR2 is a receptor of CXCL2 which was highly expressed in PMN-MDSC, andplay an important role in MDSCs recruitment (122).”
BackgroundChang, A. L., Miska, J., Wainwright, D. A., Dey, M., Rivetta, C. V., Yu, D., Kanojia, D., Pituch, K. C., Qiao, J., Pytel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0144 · Cited by 640
Ostrand-Rosenberg, S., Sinha, P., Beury, D. W., & Clements, V. K. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.011 · Cited by 583
Katoh, H., Wang, D., Daikoku, T., Sun, H., Dey, S. K., & DuBois, R. N. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.009 · Cited by 477
Alfaro, C., Teijeira, A., Oñate, C., Pérez, G., Sanmamed, M. F., Andueza, M. P., Alignani, D., Labiano, S., Azpilikueta, A., Rodriguez-Paulete, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2463 · Cited by 417 · cited 1×
“IL-8 (CXCL8) is a pro-inflammatory chemokine produced by many cell types, including glioma, and can promote MDSC trafficking into the tumor microenvironment through the IL-8/IL-8R axis (52, 53).”
BackgroundOrillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373 · cited 1×
“Entinostat (MS275), a class I HDAC inhibitor in pre-clinical testing for glioblastoma, can inhibit MDSC function and exhibit antitumor effect in murine models of lung and renal cell carcinoma (133, 134).”
BackgroundER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.
Condamine, T., Kumar, V., Ramachandran, I. R., Youn, J.-I., Celis, E., Finnberg, N., El-Deiry, W. S., Winograd, R., Vonderheide, R. H., English, N. R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74056 · Cited by 365 · cited 1×
“Many studies support a role for NF-related apoptosis-induced ligand receptors (TRAIL-Rs) act as potential targets for selective elimination of MDSCs (103).”
BackgroundVetsika, E.-K., Koukos, A., & Kotsakis, A. (2019) · Cells · doi:10.3390/cells8121647 · Cited by 125
Cited by
Gangoso, E., Southgate, B., Bradley, L., Rus, S., Galvez-Cancino, F., McGivern, N., Güç, E., Kapourani, C.-A., Byron, A., Ferguson, K. M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.023 · Cited by 359
Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
Yang, C., Xia, B.-R., Zhang, Z.-C., Zhang, Y.-J., Lou, G., & Jin, W.-L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577869 · Cited by 350
Self-citationImmunotherapy for glioblastoma: current state, challenges, and future perspectives
Liu, Y., Zhou, F., Ali, H., Lathia, J. D., & Chen, P. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01226-x · Cited by 336
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 287
The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y. (2021) · Cells · doi:10.3390/cells10030484 · Cited by 169
“However, the BBB is disrupted by inflammation, rapid expansion of GBM tumors, and tumor infiltration by immunosuppressive immune cells from blood circulation categorizing it as a ‘cold’ tumor [130].”
Background
Metadata
- Authors
- Mi, Y., Guo, N., Luan, J., Cheng, J., Hu, Z., Jiang, P., Jin, W., & Gao, X.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-04-24
- Volume
- 11
- Pages
- 737-737
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3016132910
- Cited by
- 149
- References
- 16
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.